Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study

Wilko Spiering; Bryan Williams; Jan Van der Heyden; Monique van Kleef; Rob Lo; Jorie Versmissen; Adriaan Moelker; Abraham Kroon; Hannes Reuter; Gary Ansel; Gregg W. Stone; Mark Bates; CALM-FIM EUR Investigators

doi:10.1016/S0140-6736(17)32337-1

Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study

Wilko Spiering^*, Bryan Williams, Jan Van der Heyden, Monique van Kleef, Rob Lo, Jorie Versmissen, Adriaan Moelker, Abraham Kroon, Hannes Reuter, Gary Ansel, Gregg W. Stone, Mark Bates, CALM-FIM EUR Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2655-2661
Number of pages	7
Journal	Lancet
Volume	390
Issue number	10113
DOIs	https://doi.org/10.1016/S0140-6736(17)32337-1
Publication status	Published - 16 Dec 2017

Keywords

ACTIVATION THERAPY
RENAL DENERVATION
CONTROLLED-TRIAL
BLOOD-PRESSURE
DOUBLE-BLIND
STIMULATION
PLACEBO
DISEASE

Access to Document

10.1016/S0140-6736(17)32337-1

Cite this

Spiering, W., Williams, B., Van der Heyden, J., van Kleef, M., Lo, R., Versmissen, J., Moelker, A., Kroon, A., Reuter, H., Ansel, G., Stone, G. W., Bates, M., & CALM-FIM EUR Investigators (2017). Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet, 390(10113), 2655-2661. https://doi.org/10.1016/S0140-6736(17)32337-1

Spiering, Wilko ; Williams, Bryan ; Van der Heyden, Jan ; van Kleef, Monique ; Lo, Rob ; Versmissen, Jorie ; Moelker, Adriaan ; Kroon, Abraham ; Reuter, Hannes ; Ansel, Gary ; Stone, Gregg W. ; Bates, Mark ; CALM-FIM EUR Investigators. / Endovascular baroreflex amplification for resistant hypertension : a safety and proof-of-principle clinical study. In: Lancet. 2017 ; Vol. 390, No. 10113. pp. 2655-2661.

@article{08d95e18ef8547b598d90b9fbd9f4fcc,

title = "Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study",

keywords = "ACTIVATION THERAPY, RENAL DENERVATION, CONTROLLED-TRIAL, BLOOD-PRESSURE, DOUBLE-BLIND, STIMULATION, PLACEBO, DISEASE",

author = "Wilko Spiering and Bryan Williams and {Van der Heyden}, Jan and {van Kleef}, Monique and Rob Lo and Jorie Versmissen and Adriaan Moelker and Abraham Kroon and Hannes Reuter and Gary Ansel and Stone, {Gregg W.} and Mark Bates and {CALM-FIM EUR Investigators}",

year = "2017",

month = dec,

day = "16",

doi = "10.1016/S0140-6736(17)32337-1",

language = "English",

volume = "390",

pages = "2655--2661",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Science",

number = "10113",

}

Spiering, W, Williams, B, Van der Heyden, J, van Kleef, M, Lo, R, Versmissen, J, Moelker, A, Kroon, A, Reuter, H, Ansel, G, Stone, GW, Bates, M & CALM-FIM EUR Investigators 2017, 'Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study', Lancet, vol. 390, no. 10113, pp. 2655-2661. https://doi.org/10.1016/S0140-6736(17)32337-1

Endovascular baroreflex amplification for resistant hypertension : a safety and proof-of-principle clinical study. / Spiering, Wilko; Williams, Bryan; Van der Heyden, Jan; van Kleef, Monique; Lo, Rob; Versmissen, Jorie; Moelker, Adriaan; Kroon, Abraham; Reuter, Hannes; Ansel, Gary; Stone, Gregg W.; Bates, Mark; CALM-FIM EUR Investigators.

In: Lancet, Vol. 390, No. 10113, 16.12.2017, p. 2655-2661.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Endovascular baroreflex amplification for resistant hypertension

T2 - a safety and proof-of-principle clinical study

AU - Spiering, Wilko

AU - Williams, Bryan

AU - Van der Heyden, Jan

AU - van Kleef, Monique

AU - Lo, Rob

AU - Versmissen, Jorie

AU - Moelker, Adriaan

AU - Kroon, Abraham

AU - Reuter, Hannes

AU - Ansel, Gary

AU - Stone, Gregg W.

AU - Bates, Mark

AU - CALM-FIM EUR Investigators

PY - 2017/12/16

Y1 - 2017/12/16

KW - ACTIVATION THERAPY

KW - RENAL DENERVATION

KW - CONTROLLED-TRIAL

KW - BLOOD-PRESSURE

KW - DOUBLE-BLIND

KW - STIMULATION

KW - PLACEBO

KW - DISEASE

U2 - 10.1016/S0140-6736(17)32337-1

DO - 10.1016/S0140-6736(17)32337-1

M3 - Article

VL - 390

SP - 2655

EP - 2661

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 10113

ER -